James R Neal - Net Worth and Insider Trading

James R Neal Net Worth

The estimated net worth of James R Neal is at least $799,533 dollars as of 2024-11-13. James R Neal is the CEO of XOMA Royalty Corp and owns about 25,382 shares of XOMA Royalty Corp (XOMA) stock worth over $799,533. Details can be seen in James R Neal's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that James R Neal has not made any transactions after 2022-07-15 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of James R Neal

James R Neal Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, James R Neal owns 7 companies in total, including XOMA Royalty Corp (XOMA) , XOMA Royalty Corp (XOMAO.PFD) , and Palisade Bio Inc (PALI) among others .

Click here to see the complete history of James R Neal’s form 4 insider trades.

Insider Ownership Summary of James R Neal

Ticker	Comapny	Transaction Date	Type of Owner
XOMA	XOMA Royalty Corp	2022-07-15	VP Business Development
XOMAO.PFD	XOMA Royalty Corp	2014-02-27	VP Business Development
PALI	Palisade Bio Inc	2021-04-27	director
		2021-09-30	director
		2023-06-27	director
		2022-11-01	director
		2022-11-01	director

James R Neal Latest Holdings Summary

James R Neal currently owns a total of 1 stock. James R Neal owns 25,382 shares of XOMA Royalty Corp (XOMA) as of July 15, 2022, with a value of $799,533.

Latest Holdings of James R Neal

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
XOMA	XOMA Royalty Corp	2022-07-15	25,382	31.50	799,533

Holding Weightings of James R Neal

James R Neal Form 4 Trading Tracker

According to the SEC Form 4 filings, James R Neal has made a total of 8 transactions in XOMA Royalty Corp (XOMA) over the past 5 years, including 2 buys and 6 sells. The most-recent trade in XOMA Royalty Corp is the sale of 25,000 shares on July 15, 2022, which brought James R Neal around $746,000.

Insider Trading History of James R Neal

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

James R Neal Trading Performance

GuruFocus tracks the stock performance after each of James R Neal's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by James R Neal is 32.42%. GuruFocus also compares James R Neal's trading performance to market benchmark return within the same time period. The performance of stocks bought by James R Neal within 3 months outperforms 3 times out of 3 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how James R Neal's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of James R Neal

Average Return

Average return per transaction

Outperforming Transactions

3 out of 3 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	38.35
Relative Return to S&P 500(%)	23.39

James R Neal Ownership Network

Ownership Network List of James R Neal

No Data

Ownership Network Relation of James R Neal

James R Neal Owned Company Details

What does XOMA Royalty Corp do?

Who are the key executives at XOMA Royalty Corp?

James R Neal is the VP Business Development of XOMA Royalty Corp. Other key executives at XOMA Royalty Corp include Chief Investment Officer Bradley Sitko , director & Interim CEO Owen Hughes , and other: See Explanation of Responses Biotechnology Value Fund L P .

XOMA Royalty Corp (XOMA) Insider Trades Summary

Over the past 18 months, James R Neal made no insider transaction in XOMA Royalty Corp (XOMA). Other recent insider transactions involving XOMA Royalty Corp (XOMA) include a net purchase of 9,100 shares made by Bradley Sitko , and a net purchase of 5,500 shares made by Owen Hughes .

In summary, during the past 3 months, insiders sold 0 shares of XOMA Royalty Corp (XOMA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of XOMA Royalty Corp (XOMA) were sold and 14,600 shares were bought by its insiders, resulting in a net purchase of 14,600 shares.

XOMA Royalty Corp (XOMA)'s detailed insider trading history can be found in Insider Trading Tracker table.

XOMA Royalty Corp Insider Transactions

No Available Data

What does XOMA Royalty Corp do?

Who are the key executives at XOMA Royalty Corp?

XOMA Royalty Corp (XOMAO.PFD) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of XOMA Royalty Corp (XOMAO.PFD) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of XOMA Royalty Corp (XOMAO.PFD) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

XOMA Royalty Corp (XOMAO.PFD)'s detailed insider trading history can be found in Insider Trading Tracker table.

XOMA Royalty Corp Insider Transactions

No Available Data

What does Palisade Bio Inc do?

Who are the key executives at Palisade Bio Inc?

James R Neal is the director of Palisade Bio Inc. Other key executives at Palisade Bio Inc include Chief Financial Officer John David Finley , Chief Medical Officer Mitchell Lawrence Jones , and Chief Operating Officer Robert Curtis Mcrae .

Palisade Bio Inc (PALI) Insider Trades Summary

Over the past 18 months, James R Neal made no insider transaction in Palisade Bio Inc (PALI). Other recent insider transactions involving Palisade Bio Inc (PALI) include a net purchase of 51,000 shares made by John David Finley , a net purchase of 31,000 shares made by Donald Allen Williams , and a net sale of 300 shares made by Robert J. Trenschel .

In summary, during the past 3 months, insiders sold 0 shares of Palisade Bio Inc (PALI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 20 shares of Palisade Bio Inc (PALI) were sold and 7,333 shares were bought by its insiders, resulting in a net purchase of 7,313 shares.

Palisade Bio Inc (PALI)'s detailed insider trading history can be found in Insider Trading Tracker table.

Palisade Bio Inc Insider Transactions

No Available Data

What does Monterey Innovation Acquisition Corp do?

Who are the key executives at Monterey Innovation Acquisition Corp?

James R Neal is the director of Monterey Innovation Acquisition Corp. Other key executives at Monterey Innovation Acquisition Corp include director & 10 percent owner Sandip I Patel , 10 percent owner Northstar Bio Ventures, Llc , and Chief Executive Officer Murat Omur .

Monterey Innovation Acquisition Corp (MTRY) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Monterey Innovation Acquisition Corp (MTRY) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Monterey Innovation Acquisition Corp (MTRY) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Monterey Innovation Acquisition Corp (MTRY)'s detailed insider trading history can be found in Insider Trading Tracker table.

Monterey Innovation Acquisition Corp Insider Transactions

No Available Data

What does Processa Pharmaceuticals Inc do?

Who are the key executives at Processa Pharmaceuticals Inc?

James R Neal is the director of Processa Pharmaceuticals Inc. Other key executives at Processa Pharmaceuticals Inc include director & 10 percent owner & President & CEO David Young , Chief Business - Strategy Off Patrick Lin , and Chief Executive Officer George K Ng .

Processa Pharmaceuticals Inc (PCSA) Insider Trades Summary

Over the past 18 months, James R Neal made no insider transaction in Processa Pharmaceuticals Inc (PCSA). Other recent insider transactions involving Processa Pharmaceuticals Inc (PCSA) include a net purchase of 81,000 shares made by David Young , a net purchase of 10,000 shares made by George K Ng , and a net purchase of 8,000 shares made by Justin W Yorke .

In summary, during the past 3 months, insiders sold 0 shares of Processa Pharmaceuticals Inc (PCSA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Processa Pharmaceuticals Inc (PCSA) were sold and 65,000 shares were bought by its insiders, resulting in a net purchase of 65,000 shares.

Processa Pharmaceuticals Inc (PCSA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Processa Pharmaceuticals Inc Insider Transactions

No Available Data

What does Peak Bio Inc do?

Who are the key executives at Peak Bio Inc?

James R Neal is the director of Peak Bio Inc. Other key executives at Peak Bio Inc include General Counsel Peter David Mccabe , 10 percent owner Sbi Kis 2016-1 Fund , and 10 percent owner 2014 Kif-sbi It Investment Fund .

Peak Bio Inc (PKBO) Insider Trades Summary

Over the past 18 months, James R Neal made no insider transaction in Peak Bio Inc (PKBO). Other recent insider transactions involving Peak Bio Inc (PKBO) include a net purchase of 190,250 shares made by Hoyoung Huh ,

In summary, during the past 3 months, insiders sold 0 shares of Peak Bio Inc (PKBO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Peak Bio Inc (PKBO) were sold and 190,250 shares were bought by its insiders, resulting in a net purchase of 190,250 shares.

Peak Bio Inc (PKBO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Peak Bio Inc Insider Transactions

No Available Data

What does Ignyte Acquisition Corp do?

Who are the key executives at Ignyte Acquisition Corp?

James R Neal is the director of Ignyte Acquisition Corp. Other key executives at Ignyte Acquisition Corp include General Counsel Peter David Mccabe , 10 percent owner Sbi Kis 2016-1 Fund , and 10 percent owner 2014 Kif-sbi It Investment Fund .

Ignyte Acquisition Corp (IGNYU) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Ignyte Acquisition Corp (IGNYU) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Ignyte Acquisition Corp (IGNYU) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Ignyte Acquisition Corp (IGNYU)'s detailed insider trading history can be found in Insider Trading Tracker table.

Ignyte Acquisition Corp Insider Transactions

No Available Data

James R Neal Mailing Address

Above is the net worth, insider trading, and ownership report for James R Neal. You might contact James R Neal via mailing address: 2910 Seventh Street, Berkeley Ca 94710.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.